Open access · CC-BY
via OpenAlex
Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis
Chao Chen, Yifan Qin, Zijun Luo, Peiqiang Mu, Jikai Wen, Yiqun Deng
Toxins · 2026 · ▲ 1 citations
Abstract
Deoxynivalenol (DON) is a globally prevalent mycotoxin that threatens food and feed safety via severe multi-organ toxicity. Previous studies indicate that DON induces cellular energy metabolism dysregulation by triggering oxidative stress and impairing mitochondrial function. During this process, nicotinamide adenine dinucleotide (NAD+), a central coenzyme in cellular energy metabolism, frequently exhibits significantly decreased intracellular levels or even complete depletion. However, the molecular mechanisms underlying the disruption of NAD+ homeostasis by DON exposure, as well as the development of targeted countermeasures, remain elusive. Using human embryonic kidney 293T (HEK293T) cells as an in vitro renal toxicity model, we dissected DON-induced NAD+ dysregulation and evaluated the protective potential of nicotinamide (NAM). DON caused significant NAD+ depletion in porcine serum (in vivo) and HEK293T cells (in vitro), which was confirmed as a key driver of cytotoxicity. Mechanistically, although DON binds and inhibits nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the NAD+ salvage pathway, neither NAMPT knockdown and overexpression nor nicotinamide mononucleotide (NMN) supplementation rescued DON-induced toxicity. Instead, DON dose-dependently activated poly(ADP-ribose) polymerase 1 (PARP1), the primary intracellular NAD+-consuming enzyme, to accelerate NAD+ depletion. PARP1 knockdown markedly attenuated DON-induced cytotoxicity, identifying PARP1 hyperactivation as the core toxic mechanism. NAM dose-dependently suppressed PARP1 activity, replenished NAD+ pools, and reversed cell injury. These findings establish PARP1-driven NAD+ depletion as an important mechanism of DON-induced renal toxicity, providing a promising intervention candidate for mitigating DON toxicity in food safety.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/toxins18050227
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Chen, C., Qin, Y., Luo, Z., Mu, P., Wen, J., & Deng, Y. (2026). Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis. <em>Toxins</em>. https://doi.org/10.3390/toxins18050227
Vancouver
Chen C, Qin Y, Luo Z, Mu P, Wen J, Deng Y. Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis. Toxins. 2026. doi:10.3390/toxins18050227.
BibTeX
@article{chao2026Nicoti,
title = {Nicotinamide Ameliorates Deoxynivalenol-Induced Injury in Renal Cells via Inhibiting PARP1 Hyperactivation and Restoring NAD+ Homeostasis},
author = {Chao Chen and Yifan Qin and Zijun Luo and Peiqiang Mu and Jikai Wen and Yiqun Deng},
journal = {Toxins},
year = {2026},
doi = {10.3390/toxins18050227},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nutrients 2022
Open access · CC-BY
NAD Supplement Alleviates Intestinal Barrier Injury Induced by Ethanol Via Protecting Epithelial Mitochondrial Function
International Journal of Molecular Sciences 2022
Open access · CC-BY
Nicotinamide Mononucleotide Supplementation Improves Mitochondrial Dysfunction and Rescues Cellular Senescence by NAD+/Sirt3 Pathway in Mesenchymal Stem Cells
Journal of Neuroscience Research 2011
Open access · OA
Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection
2016
Preprint · OA
Novel NAD+ metabolomic technologies and their applications to Nicotinamide Riboside interventions
Molecular Medicine Reports 2019
Open access · CC-BY
Growth differentiation factor 11 is involved in isoproterenol‑induced heart failure
Current Opinion in Cardiology 2026
Citation only